

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of August 1 - 5, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

- | | | | |
|----------|----------|------------|--|
| Thursday | 08/04/11 | 8:00 a.m. | Call Center Meeting |
| | | | <u>Resident Lectures:</u> |
| | | 8:00 a.m. | PGY-2 – “Anatomy of the Psychiatric Consult”
Dr. Barbara Lubrano |
| | | | PGY-3 and 4 – “Ethics in Psychiatry” Dr. Isis Marrero |
| | | | CHILD – “Bipolar Disorder” Dr. Mark Cavitt |
| | | 9:00 a.m. | PGY-2, 3 and 4 – “Clinical Case Conference”
Dr. Kailie Shaw and Elizabeth Reese, LCSW |
| | | | CHILD – “Bipolar Disorder” Dr. Mark Cavitt |
| | | 10:00 a.m. | PGY-2, 3 and 4 – “PRITE Review” Dr. Nadia Quijije |
| | | | CHILD – “Autism” Dr. Sandra Stock |
| | | 11:00 a.m. | Residents Meeting |
| | | 12:00 noon | NO GRAND ROUNDS |
| Friday | 08/05/11 | | No Medical Student Lectures |

In The Know!

On Monday, August 1st from 7:00 – 9:00 p.m. (in Spanish), The Carter-Jenkins Center will present: Adolescencia: Reflexiones Teórico- Clínicas, por la Licenciada Estela Bichi, Analista de Entrenamiento, Asociación Psicoanalítica de Buenos Aires.”

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing

depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator - Carlos Santana, M.D.

Schizophrenia PRIDE Study - Jail Recidivism

A 15- month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator - Jean Fils, M.D.

NEW AUTISM STUDY

We are happy to announce USF Psychiatry's participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases - a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator - Mike Bengtson, MD.

Now Open and Enrolling - ADHD Aggression Study

Kids between the ages of 6-12 years old and in generally good health with a diagnosis of ADHD are eligible to participate in a 10-week investigational medication trial . Children must be receiving stimulant medication treatment for ADHD symptoms for 1 month prior to study enrollment and be experiencing aggressive behaviors. This study is a 10 week investigational medication trial that will test the effectiveness and safety of molindone hydrochloride extended release as an add-on treatment for aggressive behaviors in children with ADHD. Principal Investigator - Mike Bengtson, MD.

Coming Soon - Bipolar I in Teens

This study is a 3- week investigational medication trial that will test the effectiveness and safety of asenapine compared to placebo in teens ages 12-17 with Bipolar I disorder who are currently experiencing a manic or mixed episode. A 26-week week extension study is available. Study medication, study visits, and required laboratory work provided at no cost. Volunteers must be between the ages of 12-17 years old and in generally good health with a diagnosis of Bipolar I disorder and currently experiencing manic or mixed symptoms. Principal Investigator - Mike Bengtson, MD.

Study-related care will include a comprehensive diagnostic exam, physical exam, laboratory testing, ECG and frequent doctor visits, as well as investigational medication, all at no charge. This is a placebo controlled trial and all participants who complete the study will have the option to enroll in an open label 6 month extension study. Enrolled patients will be compensated for time and travel.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>